4-Chloropyrrolo[2,3-d]pyrimidine CAS 3680-69-1 Purity >98.0% (HPLC) Tofacitinib Citrate Intermediate

Short Description:

Chemical Name: 4-Chloropyrrolo[2,3-d]pyrimidine

Synonyms: 4-Chloro-7H-Pyrrolo[2,3-d]pyrimidine

CAS: 3680-69-1

Purity: >98.0% (HPLC)

Appearance: Off-White or Light Yellow Powder

Intermediate of Tofacitinib Citrate (CAS: 540737-29-9)

Contact: Dr. Alvin Huang

Mobile/Wechat/WhatsApp: +86-15026746401

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

3680-69-1 - Description:

Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer of 4-Chloropyrrolo[2,3-d]pyrimidine (4-Chloro-7H-Pyrrolo[2,3-d]pyrimidine) (CAS: 3680-69-1) with high quality, intermediate of Tofacitinib Citrate (CAS: 540737-29-9). Ruifu Chemical has been supplying pharmaceutical intermediates and APIs, fine chemicals more than 15 years. Ruifu Chemical can provide worldwide delivery, competitive price, excellent service.
Purchase 4-Chloropyrrolo[2,3-d]pyrimidine or other products, please contact us by e-mail: alvin@ruifuchem.com

Intermediates of Tofacitinib Citrate:

Tofacitinib Citrate	CAS 540737-29-9
4-Chloropyrrolo[2,3-d]Pyrimidine	CAS 3680-69-1
4-Chloro-7-Tosyl-7H-Pyrrolo[2,3-d]Pyrimidine	CAS 479633-63-1
(3R,4R)-1-Benzyl-N,4-Dimethylpiperidin-3-Amine Dihydrochloride	CAS 1062580-52-2
(3R,4R)-1-Benzyl-N,4-Dimethylpiperidin-3-Amine	CAS 477600-70-7
2,4-Dichloro-7H-Pyrrolo[2,3-d]Pyrimidine	CAS 90213-66-4
(2R,3R)-2,3-Bis[(4-methylbenzoyl)oxy]butanedioic acid compd. with (3R,4R)-N,4-dimethyl-1-(phenylmethyl)-3-piperidinamine	CAS: 477600-71-8

3680-69-1 - Chemical Properties:

Chemical Name	4-Chloropyrrolo[2,3-d]pyrimidine
Synonyms	4-Chloro-7H-Pyrrolo[2,3-d]pyrimidine; 4-Chloropyrrolo[2,3-δ]pyrimidine; 6-Chloro-7-Deazapurine
Stock Status	In Stock, Commercial Production
CAS Number	3680-69-1
Molecular Formula	C6H4ClN3
Molecular Weight	153.57 g/mol
Melting Point	188.0~194.0℃
Density	1.61±0.10 g/cm3
Solubility	Soluble in DMSO, Ethyl Acetate and Methanol
Storage Temperature	Store Long-Term at 2~8℃
COA & MSDS	Available
Origin of Product	Shanghai, China
Product Categories	Pharmaceutical Intermediates
Brand	Ruifu Chemical

3680-69-1 - Specifications:

Items	Specifications	Results
Appearance	Off-White or Light Yellow Powder	Off-White Powder
Loss on Drying	<0.50%	0.30%
Max. Single Impurity	<1.00%	0.35%
Total Impurities	<2.00%	0.80%
Purity / Analysis Method	>98.0% (HPLC)	99.2%
1H NMR Spectrum	Consistent with Structure	Conforms
LCMS	Consistent with Structure	Conforms
Conclusion	The product has been tested and complies with the given specifications
Application	Intermediate of Tofacitinib Citrate (CAS: 540737-29-9)

3680-69-1 - Package/Storage/Shipping:

Package: Fluorinated bottle, Aluminium foil bag, 25kg/cardboard drum, or according to customer's requirement.
Storage Condition: Keep the container tightly closed and store in a cool, dry (2~8℃), well-ventilated warehouse. Keep away from sunshine; avoid fire and heat sources; avoid moisture. Store away from oxidizing agents.
Shipping: Deliver to worldwide by air, by FedEx / DHL Express. Provide fast and reliable delivery.

3680-69-1 - Advantages:

Sufficient Capacity: Sufficient facilities and technicians

Professional Service: One stop purchasing service

OEM Package: Custom package and label available

Fast Delivery: If within stock, three days delivery guaranteed

Stable Supply: Maintain reasonable stock

Technical Support: Technology solution available

Custom Synthesis Service: Ranged from grams to kilos

High Quality: Established a complete quality assurance system

3680-69-1 - FAQ:

How to Purchase? Please contact Dr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com

15 Years Experience? We have more than 15 years of experience in the manufacture and export of a wide range of high quality pharmaceutical intermediates or fine chemicals.

Main Markets? Sell to domestic market, North America, Europe, India, Korea, Japanese, Australia, etc.

Advantages? Superior quality, affordable price, professional services and technical support, fast delivery.

Quality Assurance? Strict quality control system. Professional equipment for analysis include NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, K.F, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, etc.

Samples? Most products provide free samples for quality evaluation, shipping cost should be paid by customers.

Factory Audit? Factory audit welcome. Please make an appointment in advance.

MOQ? No MOQ. Small order is acceptable.

Delivery Time? If within stock, three days delivery guaranteed.

Transportation? By Express (FedEx, DHL), by Air, by Sea.

Documents? After sales service: COA, MOA, ROS, MSDS, etc. can be provided.

Custom Synthesis? Can provide custom synthesis services to best fit your research needs.

Payment Terms? Proforma invoice will be sent first after confirmation of order, enclosed our bank information. Payment by T/T (Telex Transfer), PayPal, Western Union, etc.

3680-69-1 - Risk and Safety:

Risk Codes
R36/37/38 - Irritating to eyes, respiratory system and skin.
R25 - Toxic if swallowed
R20/21/22 - Harmful by inhalation, in contact with skin and if swallowed.
Safety Description
S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
S37 - Wear suitable gloves.
S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)
S36 - Wear suitable protective clothing.
UN IDs UN 2811 6.1/PG 3
WGK Germany 3
RTECS UY9360000
TSCA No
HS Code 2933599099
Hazard Class IRRITANT
Packing Group Ⅲ

3680-69-1 - Application:

4-Chloropyrrolo[2,3-d]pyrimidine (4-Chloro-7H-Pyrrolo[2,3-d]pyrimidine) (CAS: 3680-69-1) is used as an intermediate of Tofacitinib Citrate (CAS: 540737-29-9). Tofacitinib Citrate, is a king of drugs developed by the US pharmaceutical company Pfizer for treating rheumatoid arthritis, trade name Xeljanz, for the treatment of methotrexate inadequate response or intolerance to severe active rheumatoid arthritis (RA) in adult patients. November 6, 2012, the US Food and Drug Administration (FDA) and Pfizer jointly announced Tofacitinib Citrate is approved for the treatment of methotrexate inadequate response or intolerance to severe active rheumatoid joints arthritis (RA) in adult patients.